Peter Kriekard, MD
Cardiovascular Disease · Colorado Springs, CONPI 1912172735
Payments from drug & device makers
Across 211 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$856
- Pfizer$480
- Amgen$431
- Heartflow, Inc.$296
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$291
- E.r. Squibb & Sons, L.L.C.$268
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,290100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $856 |
| Pfizer | 26 | $480 |
| Amgen | 26 | $431 |
| Heartflow, Inc. | 9 | $296 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $291 |
| E.r. Squibb & Sons, L.L.C. | 15 | $268 |
| Edwards Lifesciences | 1 | $151 |
| Merck | 8 | $148 |
| Scpharmaceuticals Inc. | 7 | $131 |
| Johnson & Johnson(2 entities) | 7 | $122 |
| Boehringer Ingelheim | 6 | $112 |
| Impulse Dynamics (USA) Inc. | 3 | $99 |
| Boston Scientific | 6 | $96 |
| Philips North America LLC | 3 | $83 |
| Cvrx, Inc. | 2 | $81 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Kestra Medical Technology Services, Inc. | 3 | $67 |
| AstraZeneca | 5 | $59 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Novo Nordisk | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 1 | $32 |
| Abiomed | 1 | $31 |
| Cleerly, Inc. | 1 | $28 |
| GE HealthCare | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Bridgebio Pharma, Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Ossur Americas, Inc. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Bayer | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Akcea Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,303 in reported general payments places this provider in the 60th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $205,248 |
| XareltoRivaroxaban | 37 | $48,615 |
| Repatha SureclickEvolocumab | 23 | $32,459 |
| EntrestoSacubitril/Valsartan | 11 | $22,835 |
| Metoprolol Succinate | 231 | $2,737 |
| Atorvastatin Calcium | 247 | $2,321 |
| Rosuvastatin Calcium | 92 | $1,456 |
| Losartan Potassium | 90 | $931 |
| Carvedilol | 109 | $884 |
| Nebivolol Hcl | 14 | $828 |
| SotalolSotalol Hcl | 31 | $814 |
| Eplerenone | 11 | $755 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 30 | $732 |
| Amlodipine Besylate | 73 | $708 |
| Lisinopril | 94 | $695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $480 | $205,248142 claims |
| Johnson & JohnsonXarelto | $122 | $48,61537 claims |
| NovartisEntresto | $856 | $22,83511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Colorado Springs
- Timothy HegemanColorado Springs$283K
- Deborah JalowiecColorado Springs$106K
- David GreenbergColorado Springs$20K
- Gary LuckasenFort Collins$11M
- Payal KohliAurora$1.7M
- Marc BonacaAurora$1.2M
- William SauerAurora$978K
- John AltmanLakewood$797K
- Nampalli VijayDenver$711K
- Brack HattlerAurora$699K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.